I am mindful of how life altering a diagnosis of cancer can be, not just for the patient, but all the loved ones in their life as well. Patients and families rightly deserve, and will always get the very best of us in intelligence and compassion, along with access to state of the art treatment which is continually improving long-term outcomes.
Fauquier Office
Fairfax Office
Medical Oncologist
Medical Oncology, Hematology, and Internal Medicine
Northwestern University Feinberg School of Medicine, Medical Oncology and Hematology
University of Michigan Health System
University of Michigan Health System
Rutgers Robert Wood Johnson Medical School
Rutgers University
Malignant hematology (leukemia, lymphoma, myeloma), lung cancer, breast cancer & Clinical Trials
Mitul Gandhi, M.D. attended Rutgers University where he graduated Magna Cum Laude with a Bachelor of Arts in Molecular Biology and Biochemistry. He earned his medical degree from Rutgers Robert Wood Johnson Medical School where he received the Robert Wood Johnson Foundation Research Award among other honors. Dr. Gandhi then completed his residency and internship in Internal Medicine at University of Michigan Health System.
Dr. Gandhi joins Virginia Cancer Specialists after serving as Chief Fellow in the Medical Oncology and Hematology Fellowship program at Northwestern University Feinberg School of Medicine. During his time at Northwestern, Dr. Gandhi actively participated in clinical research, with a focus in high risk lymphoma. He has presented at major national meetings, won the American Society of Hematology’s Abstract Achievement Award in 2013, and has several publications including a recent article in Blood on double hit lymphomas. Dr. Gandhi is currently an Associate Member of both the American Society of Hematology and the American Society of Clinical Oncology.
In his spare time, Dr. Gandhi enjoys traveling with his wife, reading and writing, and spending time with family and friends.
Dr. Mitul Gandhi, Medical Oncologist at Virginia Cancer Specialists, Co-Authors Real-World Study Assessing Efficacy of Azacitidine in Treatment-Naive Patients with Higher-Risk Myelodysplastic Syndromes
Read MoreVirginia Cancer Specialists Participating in National Pilot Project to Increase Diversity in Cancer Treatment Trials
Read MoreVirginia Cancer Specialists Opens New Office in Fauquier -- Expanding Access to Cancer Care, Research and Clinical Trials
Read MoreMitul Gandhi, MD - Myeloma: Symptoms, Treatment, and the Role of Clinical Trials Event - March 25 2021
Read MoreDr. Mitul Gandhi, highlights key abstracts from the #ASCO20 Virtual Scientific Program that aim to improve outcomes for patients with multiple myeloma
Read MorePractice Message Covid19 and Cancer: Cancer Doesn't Stop in a Pandemic
Read MoreSafety and Antitumor Activity Study Evaluating Loncastuximab Tesirine and Rituximab Versus Immunochemotherapy in Diffuse Large B-Cell Lymphoma
Read MoreNHL Patients and Nurses in the US Prefer Subcutaneous Rituximab Injection Versus Intravenous Rituximab Infusion: A Real-World Study
Read MoreImpact of oncogene rearrangement patterns on outcomes in patients with double-hit non-Hodgkin lymphoma.
Read MorePancreatitis in patients treated with Brentuximab Vedotin: A previously unrecognized serious adverse
Read MorePredicting benefit from imatinib. Are we close? Leukemia and Lymphoma.
Read MoreTargeted treatment of head and neck squamous cell carcinoma: potential of lapatinib.
Read MoreImpact of Induction Regimen and Consolidative Stem Cell Transplantation in Double Hit Lymphoma (DHL)
Read MoreAssociation of implantable defibrillator therapy risk with body mass index in systolic heart failure
Read MoreBrentuximab Vedotin in Patients with Relapsed HIV-Related Lymphoma
Read More